Drug Profile
NAL 3210
Alternative Names: NAL-3210Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Onychomycosis
Most Recent Events
- 26 May 2022 NAL 3210 is still in clinical trials in Onychomycosis (NAL Pharma pipeline, May 2022)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Onychomycosis in Unknown (Topical, Liquid)
- 09 Sep 2016 NAL 3210 is available for licensing as of 09 Sep 2016. http://www.nalpharma.com/licensing.php?id=10&lang=en